Cell and gene therapy strategies to eradicate HIV reservoirs.

PubWeight™: 0.80‹?›

🔗 View Article (PMID 27031009)

Published in Curr Opin HIV AIDS on July 01, 2016

Authors

Chelsea Spragg1, Harshana De Silva Feelixge, Keith R Jerome

Author Affiliations

1: aVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA bDepartment of Laboratory Medicine, University of Washington, Seattle, Washington, USA.

Associated clinical trials:

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients | NCT01044654

Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects | NCT01252641

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients | NCT02500849

Articles citing this

Why cure, why now? J Med Ethics (2016) 0.80

Disruption or Excision of Provirus as an Approach to HIV Cure. AIDS Patient Care STDS (2016) 0.75

Articles cited by this

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99

Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75

Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 11.68

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med (2009) 8.45

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood (2011) 8.26

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76

Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64

Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med (2013) 6.63

Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol (2010) 6.55

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38

Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 6.14

Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood (2010) 4.99

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature (2013) 3.90

Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature (2011) 3.80

Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med (2009) 3.25

Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med (2014) 3.24

Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature (2013) 3.14

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature (2015) 2.87

Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 2.84

Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell (2014) 2.55

The AAV vector toolkit: poised at the clinical crossroads. Mol Ther (2012) 2.53

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood (2010) 2.52

Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep (2013) 2.48

Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med (2014) 2.39

RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A (2014) 2.32

Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Exp Hematol (2006) 2.32

Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci U S A (2014) 2.23

Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS (2010) 2.03

Molecular cloning and characterization of a murine pre-B-cell growth-stimulating factor/stromal cell-derived factor 1 receptor, a murine homolog of the human immunodeficiency virus 1 entry coreceptor fusin. Proc Natl Acad Sci U S A (1996) 1.95

Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet (2015) 1.86

Revisiting immune exhaustion during HIV infection. Curr HIV/AIDS Rep (2011) 1.62

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med (2014) 1.59

PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing. PLoS Pathog (2015) 1.49

Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci U S A (2015) 1.49

Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection. Proc Natl Acad Sci U S A (2014) 1.49

Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res (2013) 1.48

CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report. Lancet HIV (2015) 1.47

Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun (2015) 1.41

Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol (2002) 1.40

Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med (2015) 1.30

Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma? Hum Gene Ther (2015) 1.25

CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS One (2014) 1.16

The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology (2015) 1.06

CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape. Mol Ther (2016) 1.06

Peripheral Vγ9Vδ2 T Cells Are a Novel Reservoir of Latent HIV Infection. PLoS Pathog (2015) 1.02

A high excision potential of TALENs for integrated DNA of HIV-based lentiviral vector. PLoS One (2015) 1.01

Persistence of virus reservoirs in ART-treated SHIV-infected rhesus macaques after autologous hematopoietic stem cell transplant. PLoS Pathog (2014) 1.01

The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol (2015) 1.00

Adeno-associated Vector Toxicity-To Be or Not to Be? Mol Ther (2015) 0.98

Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. J Gen Virol (2015) 0.97

Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy. Antiviral Res (2015) 0.97

Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep (2015) 0.94

Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. J Virol (2015) 0.91

mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5. Nucleic Acids Res (2015) 0.91

Engineering Cellular Resistance to HIV-1 Infection In Vivo Using a Dual Therapeutic Lentiviral Vector. Mol Ther Nucleic Acids (2015) 0.88

HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells. Mol Ther (2015) 0.88

AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity. PLoS Pathog (2015) 0.87

CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus. Mol Ther Nucleic Acids (2015) 0.87

Efficient genome editing in hematopoietic stem cells with helper-dependent Ad5/35 vectors expressing site-specific endonucleases under microRNA regulation. Mol Ther Methods Clin Dev (2015) 0.86

HIV Excision Utilizing CRISPR/Cas9 Technology: Attacking the Proviral Quasispecies in Reservoirs to Achieve a Cure. MOJ Immunol (2014) 0.85

Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. Nucleic Acids Res (2015) 0.85

Host Anti-antibody Responses Following Adeno-associated Virus-mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys. Mol Ther (2015) 0.83

Dependence on the CCR5 coreceptor for viral replication explains the lack of rebound of CXCR4-predicted HIV variants in the Berlin patient. Clin Infect Dis (2014) 0.82

Engineering T Cells to Functionally Cure HIV-1 Infection. Mol Ther (2015) 0.81

Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors. J Immunol (2015) 0.80

Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice. J Virol (2015) 0.80

Preclinical Assessment of Mutant Human TRIM5α as an Anti-HIV-1 Transgene. Hum Gene Ther (2015) 0.79

PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia. PLoS Pathog (2015) 0.79

HIV-1 CCR5 gene therapy will fail unless it is combined with a suicide gene. Sci Rep (2015) 0.79

Effective inhibition of HIV-1 production by short hairpin RNAs and small interfering RNAs targeting a highly conserved site in HIV-1 Gag RNA is optimized by evaluating alternative length formats. Antimicrob Agents Chemother (2015) 0.78

Short communication: Efficiently inhibiting HIV-1 replication by a prototype foamy virus vector expressing novel H1 promoter-driven short hairpin RNAs. AIDS Res Hum Retroviruses (2015) 0.78

Generation of CCR5-defective CD34 cells from ZFN-driven stop codon-integrated mesenchymal stem cell clones. J Biomed Sci (2015) 0.78

Gene transfer of two entry inhibitors protects CD4(+) T cell from HIV-1 infection in humanized mice. Gene Ther (2015) 0.77

Ectopic expression of anti-HIV-1 shRNAs protects CD8(+) T cells modified with CD4ζ CAR from HIV-1 infection and alleviates impairment of cell proliferation. Biochem Biophys Res Commun (2015) 0.77

CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy. J Infect Dis (2015) 0.77

Stable Delivery of CCR5-Directed shRNA into Human Primary Peripheral Blood Mononuclear Cells and Hematopoietic Stem/Progenitor Cells via a Lentiviral Vector. Methods Mol Biol (2016) 0.76

Gene therapy strategies to block HIV-1 replication by RNA interference. Adv Exp Med Biol (2015) 0.76

Differential evolution of a CXCR4-using HIV-1 strain in CCR5wt/wt and CCR5∆32/∆32 hosts revealed by longitudinal deep sequencing and phylogenetic reconstruction. Sci Rep (2015) 0.76

Articles by these authors

Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol (2006) 3.38

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol (2006) 2.62

Viral diagnostics in the era of digital polymerase chain reaction. Diagn Microbiol Infect Dis (2012) 1.72

Clinical correlates of herpes simplex virus viremia among hospitalized adults. Clin Infect Dis (2009) 1.69

Marked variability of BK virus load measurement using quantitative real-time PCR among commonly used assays. J Clin Microbiol (2008) 1.60

Identification of chromosomally integrated human herpesvirus 6 by droplet digital PCR. Clin Chem (2014) 1.48

Implementation of filmarray respiratory viral panel in a core laboratory improves testing turnaround time and patient care. Am J Clin Pathol (2013) 1.46

Coreactivation of Human Herpesvirus 6 and Cytomegalovirus Is Associated With Worse Clinical Outcome in Critically Ill Adults. Crit Care Med (2015) 1.45

Quantitation of cytomegalovirus DNA load in dried blood spots correlates well with plasma viral load. J Clin Microbiol (2013) 1.42

Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology (2009) 1.40

Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol (2012) 1.36

Evaluation of real-time PCR versus PCR with liquid-phase hybridization for detection of enterovirus RNA in cerebrospinal fluid. J Clin Microbiol (2003) 1.35

Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell (2012) 1.33

Tolerance of droplet-digital PCR vs real-time quantitative PCR to inhibitory substances. Clin Chem (2013) 1.33

Successful targeting and disruption of an integrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI. PLoS One (2011) 1.21

Use of the MagNA pure LC automated nucleic acid extraction system followed by real-time reverse transcription-PCR for ultrasensitive quantitation of hepatitis C virus RNA. J Clin Microbiol (2004) 1.16

Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract. Elife (2013) 1.12

Polyomavirus nephropathy in native kidneys of non-renal transplant recipients. Am J Transplant (2005) 1.10

Targeted gene disruption to cure HIV. Curr Opin HIV AIDS (2013) 1.09

Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant (2003) 1.08

Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis (2013) 1.05

Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach. PLoS Comput Biol (2013) 1.05

Inhibition of TCR signaling by herpes simplex virus. J Immunol (2006) 1.03

The virological synapse facilitates herpes simplex virus entry into T cells. J Virol (2009) 1.03

Comparison of FilmArray Respiratory Panel and laboratory-developed real-time reverse transcription-polymerase chain reaction assays for respiratory virus detection. Diagn Microbiol Infect Dis (2012) 1.01

Calibration curves for real-time PCR. Clin Chem (2005) 1.01

Cytomegalovirus quantitation by real-time PCR is unaffected by delayed separation of plasma from whole blood. J Clin Microbiol (2004) 0.99

Herpes simplex virus remodels T-cell receptor signaling, resulting in p38-dependent selective synthesis of interleukin-10. J Virol (2007) 0.99

Rapid detection directly from patient serum samples of human cytomegalovirus UL97 mutations conferring ganciclovir resistance. J Clin Microbiol (2007) 0.98

Comparison of a multiplex real-time PCR assay with a multiplex Luminex assay for influenza virus detection. J Clin Microbiol (2013) 0.97

Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med (2015) 0.96

CTL are inactivated by herpes simplex virus-infected cells expressing a viral protein kinase. J Immunol (2003) 0.95

A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant (2005) 0.94

Apoptosis and antigen receptor function in T and B cells following exposure to herpes simplex virus. Virology (2006) 0.93

Comparison of the Simplexa FluA/B & RSV direct assay and laboratory-developed real-time PCR assays for detection of respiratory virus. J Clin Microbiol (2013) 0.92

Multiplex real-time reverse transcription-PCR assay for determination of hepatitis C virus genotypes. J Clin Microbiol (2006) 0.91

Prevalence, clinical and virologic outcomes of hepatitis B virus co-infection in HIV-1 positive Kenyan women on antiretroviral therapy. PLoS One (2013) 0.91

Herpes simplex virus genes Us3, Us5, and Us12 differentially regulate cytotoxic T lymphocyte-induced cytotoxicity. Viral Immunol (2006) 0.89

The antiapoptotic herpes simplex virus glycoprotein J localizes to multiple cellular organelles and induces reactive oxygen species formation. J Virol (2007) 0.88

Apoptosis prevention as a mechanism of immune evasion. Int Rev Immunol (2003) 0.88

Cell type-specific induction and inhibition of apoptosis by Herpes Simplex virus type 2 ICP10. J Virol (2008) 0.87

Cell-type-specific tyrosine phosphorylation of the herpes simplex virus tegument protein VP11/12 encoded by gene UL46. J Virol (2008) 0.85

The potential advantages of digital PCR for clinical virology diagnostics. Expert Rev Mol Diagn (2014) 0.84

Herpes simplex virus-associated sepsis in a previously infected immunocompetent adult. Ann Intern Med (2003) 0.84

Comparison of methods for extraction of viral DNA from cellular specimens. Diagn Microbiol Infect Dis (2009) 0.83

Allele-specific PCR for determination of IL28B genotype. J Clin Microbiol (2012) 0.83

Investigation of epstein-barr virus as a potential cause of B-cell non-Hodgkin lymphoma in a prospective cohort. Cancer Epidemiol Biomarkers Prev (2013) 0.83

Assessment of mitochondrial toxicity by analysis of mitochondrial protein expression in mononuclear cells. Cytometry B Clin Cytom (2009) 0.82

Robust suppression of env-SHIV viremia in Macaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infection. J Med Primatol (2013) 0.81

Measuring T-cell-mediated cytotoxicity using antibody to activated caspase 3. Nat Med (2003) 0.81

Hepatitis C virus activation in HIV-infected patients initiating highly active antiretroviral therapy. AIDS Patient Care STDS (2007) 0.81

Type-specific identification of anogenital herpes simplex virus infections by use of a commercially available nucleic acid amplification test. J Clin Microbiol (2012) 0.80

Lack of viral control and development of combination antiretroviral therapy escape mutations in macaques after bone marrow transplantation. AIDS (2015) 0.77

TALENs targeting HBV: designer endonuclease therapies for viral infections. Mol Ther (2013) 0.76

Mass spectrometry for genotyping hepatitis C virus: a promising new approach. Clin Chem (2005) 0.75

Rapid detection of human cytomegalovirus UL97 and UL54 mutations directly from patient samples. J Clin Microbiol (2013) 0.75

Quantification of mitochondrial toxicity in HIV-infected individuals by quantitative PCR compared to flow cytometry. Cytometry B Clin Cytom (2012) 0.75

Attitudes and Willingness to Assume Risk of Experimental Therapy to Eradicate Genital Herpes Simplex Virus Infection. Sex Transm Dis (2016) 0.75

Performance of Commercial Enzyme-Linked Immunoassays for Diagnosis of Herpes Simplex Virus-1 and Herpes Simplex Virus-2 Infection in a Clinical Setting. Sex Transm Dis (2017) 0.75

Cervicovaginal shedding of hepatitis C viral RNA is associated with the presence of menstrual or other blood in cervicovaginal fluids. J Clin Virol (2010) 0.75

Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications. Emerg Infect Dis (2022) 0.75

Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate. medRxiv (2020) 0.75